Product Review: Durvalumab (Imfinzi™) in the treatment of Stage III non-small cell lung cancer

In this review:

Durvalumab (Imfinzi™) is a programmed cell death ligand-1 (PD-L1) inhibitor that is indicated for patients with locally advanced or metastatic urothelial carcinoma, small cell lung cancer (SCLC) and locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC). The combination of chemoradiation therapy and durvalumab offers NSCLC patients another treatment option, in a disease with historically low survival rates. This review focusses on the mechanism of action for PD-L1 inhibitors such as durvalumab following chemoradiation, the key pharmacological characteristics of the molecule and the data from NSCLC clinical trials.

Please login below to download this issue (PDF)